AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

www.astrazeneca.com

AstraZeneca RSS Channel

Filters
List of articles in category AstraZeneca
Title Published Date
Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients with EGFR mutation-positive non-small cell lung cancer 11 October 2017
Bevespi Aerosphere demonstrates statistically significant improvement in lung function in patients with COPD 25 September 2017
AstraZeneca presents new results identifying severe asthma patients who would benefit most from benralizumab 12 September 2017
Tezepelumab significantly reduced asthma exacerbations for a broad population of patients with severe uncontrolled asthma 06 September 2017
AstraZeneca and Takeda establish collaboration to develop and commercialise MEDI1341 for Parkinson's disease 29 August 2017
Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack 24 August 2017
US FDA accepts regulatory submission for acalabrutinib and grants Priority Review 02 August 2017
AstraZeneca and Merck establish strategic oncology collaboration 27 July 2017
AstraZeneca enters agreement with Grünenthal to divest rights to migraine treatment Zomig 08 June 2017
AstraZeneca enters agreement with Recordati for Seloken in Europe 22 May 2017

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs